PVCT · XBRL financial data

Provectus Biopharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PVCT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	—	—	989	558	617	336
Research and development	2,813	2,608	2,389	1,749	1,999	1,897
General and administrative	2,151	2,064	2,028	1,710	3,150	3,734
Total operating expenses	4,964	4,672	4,417	3,459	5,150	5,631
Operating income (loss)	(4,964)	(4,672)	(3,428)	(2,901)	(4,532)	(5,295)
Interest income	3	0	—	—	—	—
Interest expense	1,748	962	3	6	14	5
Net income (loss)	(6,678)	(5,540)	(3,555)	(3,102)	(4,733)	(5,431)
Earnings per share, basic USD per share	—	(0.01)	(0.01)	(0.01)	(0.01)	(0.01)
Earnings per share, diluted USD per share	—	—	(0.01)	(0.01)	(0.01)	(0.01)
Weighted average shares, basic thousands of shares	—	408,223	419,470	419,508	419,810	420,280
Weighted average shares, diluted thousands of shares	—	—	419,470	419,508	419,810	420,280

Fiscal years (PVCT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	97	683	22	77	307	251
Prepaid and other current assets	—	—	467	338	487	317
Total current assets	424	3,442	1,899	1,365	977	568
Property and equipment, net	45	32	21	12	5	3
Right-of-use asset	121	40	117	72	25	127
Total assets	589	3,513	2,037	1,449	1,006	698
Accounts payable	957	1,287	2,094	1,676	1,107	716
Total current liabilities	30,712	7,701	8,192	9,017	6,975	6,897
Lease liability, non-current	45	—	73	25	—	79
Total liabilities	30,796	7,701	8,266	9,042	6,975	7,000
Accumulated deficit	(240,494)	(246,034)	(249,589)	(252,690)	(257,423)	(262,854)
Total stockholders' equity	(30,206)	(4,187)	(6,229)	(7,593)	(5,959)	(6,299)
Total liabilities and equity	589	3,513	2,037	1,449	1,006	698
Common shares outstanding (cover page) thousands of shares	403,557	419,447	419,497	419,522	420,280	420,280

Fiscal years (PVCT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(6,678)	(5,540)	(3,555)	(3,102)	(4,733)	(5,431)
Stock-based compensation	135	24	3	3	1,281	1,238
Net cash from operating activities	(4,086)	(1,013)	(3,041)	(2,572)	(3,284)	(3,326)
Net cash from financing activities	3,600	4,024	1,368	2,192	2,748	3,087
Net change in cash	(493)	3,010	(1,675)	(405)	(537)	(238)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Provectus Biopharmaceuticals	1,157	not reported	(358)*	420.3M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Tempest Therapeutics	779	not reported	(2,779)*	16.0M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
ProMIS Neurosciences	53,429	not reported	(10,385)*	9.0M	5.1 quarters	Q2 FY26 10-QJun 30, 2026
Cumberland Pharmaceuticals	3,862	166	169*	15.0M	—	Q2 FY26 10-QJun 30, 2026
Yarrow Bioscience	22,925	97	(1,992)*	2.7M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Rein Therapeutics	8,542	0	(8,640)*	86.3M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Insight Molecular Diagnostics	17,756	239	(9,268)*	32.7M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Rockwell Medical	10,519	not reported	2,080*	4.0M	—	Q2 FY26 10-QJun 30, 2026
Champions Oncology	4,358	15,232	(492)	13.9M	8.0 quarters	Q1 FY27 10-QJul 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.